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Background: Arterial and venous thrombotic events are more prevalent in HIV infected
individuals compared to the general population, even in the era of combination
antiretroviral therapy. Although the mechanism is not fully understood, recent evidence
suggests a role for chronic immune activation.
Methods: We reviewed the Dutch National HIV registry database for HIV infected
patients in Rotterdam with a history of arterial or venous thrombosis and calculated
the incidence. We collected samples from patients with and without thrombosis and
compared plasma levels of lipopolysaccharide (LPS), LPS binding protein (LBP), soluble
CD14 (sCD14), and von Willebrand Factor antigen level (vWF).
Results: During a 10-year period, a total of 60 documented events in 14,026 person
years of observation (PYO) occurred, resulting in an incidence rate of 2.50, 2.21, and
4.28 for arterial, venous and combined thrombotic events per 1000 PYO, respectively.
The vWF was elevated in the majority of study subjects (mean 2.36 SD± 0.88 IU/ml); we
found a significant difference when comparing venous cases to controls (mean 2.68 SD
± 0.82 IU/ml vs. 2.20 SD ± 0.77 IU/ml; p = 0.024). This difference remained significant
for recurrent events (mean 2.78 SD ± 0.75; p = 0.043). sCD14 was positively correlated
with LPS (r = 0.255; p = 0.003).
Conclusion: The incidence of venous thrombosis was two-fold higher in HIV infected
patients compared to age-adjusted data from general population cohort studies. We
couldn’t find a clear association between immune activation markers to either arterial or
venous thrombotic events. We observed a marked increase in vWF levels as well as a
correlation of vWF to first and recurrent venous thrombo-embolic events. These findings
suggest that HIV infection is an independent risk factor for coagulation abnormalities and
could contribute to the observed high incidence in venous thrombosis. This could be a
reason to prolong anti-thrombotic treatment in HIV patients with a history of thrombosis.
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Introduction
The delicate interaction between inflammation and coagula-
tion has long been recognized and persists to play a pivotal
role in numerous infections such as sepsis and viral hemor-
rhagic diseases. In chronic HIV infection, the hemostatic bal-
ance is tipped toward a more pro-coagulant status, resulting in
thrombosis (Goeijenbier et al., 2012). This is supported by both
epidemiological and experimental data.
The annual risk on venous thrombosis in a representable
European population below the age of 60 is slightly over 1 per
1000 person years of observation (PYO) (Oger, 2000; Naess et al.,
2007). For arterial thrombosis, the annual risk is higher with
incidence rates between 2 and 3 per 1000 PYO for myocardial
infarction and around 0.65 per 1000 PYO for stroke (Vaartjes
et al., 2013; Van Oeffelen et al., 2014). It is likely that HIV infec-
tion independently adds to this risk (Shen and Frenkel, 2004).
A nationwide study comprising of 4333 HIV infected individu-
als reported an incidence of venous thrombosis in 3.2 per 1000
PYO (Rasmussen et al., 2011). In addition, events occur at a
significantly younger age compared to the control population
(Copur et al., 2002; Malek et al., 2011). Similar trends have been
observed in myocardial infarction (Esser et al., 2013), stroke
(Marcus et al., 2014) and peripheral atherosclerosis (Periard et al.,
2008). A large tri-continental study determined an incidence of
5.7 per 1000 PYO for first cardio- or cerebrovascular event in
a relatively young cohort (d’Arminio et al., 2004) with cumula-
tive exposure to cART as a major contributor (Friis-Møller et al.,
2003a,b).
The exact pathophysiology of increased thrombotic activity
in HIV remains unknown but recent publications advocate
a role for chronic immune activation. In this hypothesis,
HIV infection causes a loss of mucosal integrity in the gut
together with CD4 T-cell depletion in local lymphoid tis-
sue. This results in translocation of microbial products from
the lumen to the circulation (Brenchley et al., 2006). Bacte-
rial endotoxins such as LPS are subsequently bound to pat-
tern recognition receptors and trigger a potent inflammatory
response in monocytes and macrophages (Kristoff et al., 2014;
Shan and Siliciano, 2014). LPS, LBP and soluble CD14 lev-
els have been found to correlate with a hypercoagulable state
in chronic HIV, with or without combined cART (Jong et al.,
2010; Sandler et al., 2011; Romero-Sánchez et al., 2012; Funder-
burg, 2014). Although it is conceivable that immune activation
accelerates clot formation, the exact mechanism remains to be
elucidated.
In this study we addressed HIV as a common risk factor for
both arterial and venous thrombosis and investigated chronic
immune activation as the proposed driving mechanism. To test
this hypothesis, we assessed the incidence of venous and arte-
rial thrombotic events in a chronically infected HIV popula-
tion. We compared coagulation (vWF), microbial translocation
(LPS and LBP) and inflammatory parameters (sCD14) of patients
with a past thrombotic event to patients without an event. We
hypothesized that HIV infected individuals with a past throm-
botic event have a higher exposure to microbial-driven immune
activation.
Materials and Methods
Patients and Study Design
On February 25th 2013, we retrieved information from the
Stichting HIV Monitoring (SHM) database, described elsewhere,
which includes anonymized data obtained from treated and
untreated HIV-infected patients, who have been followed in or
after 1996 in our hospital (Van Sighem et al., 2013). Cases were
defined as patients with a thrombotic event and a presumed or
definite preceding HIV diagnosis. A preceding HIV status was
presumed when the CD4 cell count was <200/mm3 within 1
year of the thrombotic event. Venous thrombo-embolic events
included deep venous thrombosis (DVT), diagnosed by com-
pression ultrasonography; or pulmonary embolism (PE), diag-
nosed by Computer Tomography (CT) pulmonary angiography.
Arterial thrombo-embolic events included myocardial infarction
(MI), diagnosed by electrocardiogram and cardiac biomarkers;
cerebrovascular incident (CVA) or ischemic attack (TIA), diag-
nosed by neurological examination in combination with CT
scan results; and claudication intermittens (CI) diagnosed by the
ankle-brachial index. Cases were compared to randomly selected
controls, i.e., patients with HIV infection but no thrombo-
embolic event in their history. This control population was com-
parable to the general HIV population in Rotterdam with respect
to age and sex. All cases and controls were offered a questionnaire
concerning classical risk factors. This research was approved by
the local ehtics committee, patients had to sign an informed
consent document to participate.
LPS, LBP, sCD14, and vWF Measurements
We collected plasma from 65 cases and 65 control patients for
analysis of LPS, LBP, sCD14, and vWF. The patient blood sam-
ples were collected in Ethylene diamine tetra acetic acid (EDTA).
These were initially intended for viral load analysis and stored at
−80◦C. The mean time from thrombotic event to blood sample
collection was 6.2 years (SD ± 4.7). Samples were thawed only
once to prevent protein degradation. LPS levels were measured
using the Pyros Kinetix Flex R© chromogenic endotoxin detection
system (Associates of Cape Cod). Plasma samples were heat inac-
tivated at 60◦C and subsequently diluted with LPS free LAL H2O
at concentrations varying from 1:20 to up to 1:400. Exact LPS
quantities were derived from a standard curve of known con-
trol endotoxin concentrations. LBP was measured using a LBP
ELISA kit R© (Hycult biotech); soluble CD14 was measured using
the Human sCD14 Quantikine ELISA Kit R© (R&D systems); vWF
antigen levels were measured with an in-house ELISA using
DAKOPATTS antibodies and compared to the vWF antigen lev-
els to commercially available pooled plasma from 20 or more
otherwise healthy donors (CRYOcheck™).
Data Analysis
For the calculation of incidence, we used available SHM data on
all HIV patients in care at the Erasmus MC from February 25th
2003 to February 25th 2013. The incidence rate of an event was
calculated as the number of documented cases occurring in a 10
year time period, divided by the total amount of unique person-
years contributed to the cohort. Data was censored when an event
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occurred, when the patient died or on the index date, whichever
came first. Cases with both arterial and venous events were cen-
sored on whichever date came first, but were included in both
calculations.
Normality of data was assessed by a Shapiro Wilk test and
inspection of Q-Q Plots. Homogeneity of variance was assessed
by Levene’s Test for Equality of Variances. An independent T-test
or Man-Whitney was performed for continuous variables when
appropriate. vWFwas normally distributed, and sCD14, LBP, and
LPS showed a non-parametric distribution. For categorical vari-
ables, a Chi-Square test was applied. Correlation analysis was per-
formed using the Spearman’s Rank-order test. A significance level
of 0.05 was applied. All statistical analysis was performed using
SPSS software, version 21 (IBM corp©). Graphs were constructed
using GraphPad Prism software, version 6.
Results
From February 25th 2003 to February 25th 2013, a total of 2731
unique patients were registered in the Rotterdam SHM database,
representing 14,026 person years. A total of 60 thrombotic events
occurred during this 10-year period. The overall incidence of
both arterial and venous thrombotic events combined was 4.28
per 1000 PYO. These rates were 2.50 and 2.21 for arterial events
and venous thrombotic events, respectively. The incidence of
patients with a recurrent event was 0.93 in the arterial group and
0.57 in the venous group per 1000 PYO when divided by the total
amount of person years. When divided by the corresponding
amount of person years in the specific event group only, the inci-
dence increased to 95 in the arterial group and 73 in the venous
group per 1000 PYO. In the group that had experienced a venous
thrombosis, the incidence of patients that had a recurrence of a
venous event was 30% after a period of 3 years.
At the time of inclusion on February 25th 2013, a total of
1679 HIV-infected patients were still in care out of which 79
were reported with a thrombotic event (see Figure 1). Of these 79
patients, 10 patients were excluded based on a negative HIV test
at the time of event and 4 patients refused participation, resulting
in 65 available cases. In addition, we searched the database for
patients that died between April 1st 2002 and November 22nd
2012 and had a history of thrombosis. In total, 223 patients died
during this period of which 20 had a documented thrombotic
event in the past. Of these 85 patients, 37 were diagnosed with
a PE or DVT; 41 with a MI, CVA or CI; and 7 had endured both
a venous and arterial event.
A random selection of the patients registered in the Rot-
terdam SHM database (as described earlier) was applied to
select a control group of 198 HIV-infected patients. This group
was comparable to the whole HIV population at the Erasmus
Medical Center in respect to age and sex. When compared to
the 198 controls at the time of observation, cases with arterial
and venous events were significantly older [46.85 SD ± 11.10 vs.
FIGURE 1 | Flow chart depicting the selection of patients for this study.
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57.83 SD ± 11.01 years p < 0.001 (arterial) vs. 52.80 SD ± 11.21
p = 0.007 (venous)], more likely to be of Caucasian descent
[46.5% vs. 70.7% p = 0.005 (arterial) vs. 67.6% p = 0.018
(venous)] and were more likely to have history of hypertension
[8.1% vs. 39% p < 0.001 (arterial) vs. 21.6% p = 0.013 (venous)]
and malignancy [6.1% vs. 19.5% p = 0.005 (arterial) vs. 21.6%
p = 0.002 (venous)]. Compared to controls, an arterial event
was specifically associated with male sex (71.2% vs. 90.2%
p = 0.011), a positive family history for cardiovascular events
(17.7% vs. 39.0% p = 0.002) and diabetes mellitus (4.5% vs.
22.0% p < 0.001). There was no difference between cases and
controls for traditional risk factors such as a high body mass
index, smoking or immobilization. No difference was found
for HIV related risk factors such as a low CD4 nadir count or
protease inhibitor (PI) use (Table 1).
For patient characteristics of subjects that underwent analysis
of sCD14, LPS, LBP, and vWF please see Supplementary Table 1.
Patients with a thrombotic event in the past had a higher mean
vWF antigen level when compared to controls (venous: 2.68 SD
± 0.82 IU/ml; arterial: 2.31 SD ± 1.10 IU/ml; both: 2.74 SD ±
0.90 IU/ml; controls: 2.20 SD ± 0.77 IU/ml). The difference in
vWF antigen levels was significant in patients with a past venous
event compared to controls (p = 0.024, Independent samples
T-test) (Figure 2), which remained significant when comparing
only recurrent events to controls (2.78 SD ± 0.75; p = 0.043
Independent Samples T-test, Figure 3). The significance of dif-
ference in vWF antigen level between cases combined vs. controls
varied upon the applied statistical test (p = 0.047, Mann Whit-
ney; p = 0.071 Independent samples T-test). There was no clear
connection between time since thrombotic event and the level
of vWF antigen (see Figure 4). There was no significant differ-
ence between cases and controls in sCD14 (median: 2.45 IQR ±
2.08 vs. 2.31 IQR ± 1.36; p = 0.341) and LBP (median: 20.19
IQR ± 17.56 vs. 16.63 IQR ± 15.05µ/ml; p = 0.264) as well as
LPS (median: 12.19 IQR± 24.70 vs. 10.76 IQR± 23.58) although
values tended to be higher in cases (Figure 2).
The only association detected was a positive correlation
between levels of soluble CD14 and log 10 levels of LPS
(p = 0.003; r = 0.255, Figure 5A). There was also a weak
trend toward positive correlation between plasma levels of vWF
and sCD14 (p = 0.078; r = 0.184, Figure 5D). The four other
combinations of markers (vWF vs. LBP; vWF vs. log 10 LPS;
sCD14 vs. LBP; LBP vs. log 10 LPS) were not correlated (all
p > 0.1) (Figures 5B,C,E,F).
Discussion
Our results confirm previous observations of thrombosis being a
prevalent co-morbidity in the HIV population, even in a cohort
with prolonged c-ART treatment. Comparable to uninfected
individuals, traditional risk factors such as diabetes, malignancy,
hypertension and a positive family history continue to contribute
to the development of an event, but additional factors play a role.
This study was aimed to investigate the incidence of arterial and
venous thrombosis in patients living with chronic HIV infection.
In addition we wanted to address what factors predispose HIV
TABLE 1 | Patient characteristics.
Controls (N = 198) Cases (85) P-value
Males (%) 141 (71.2) 70 (82.4) 0.049
Venous events only 28 (75.7) 0.579
Arterial events only 37 (90.2) 0.011
Both events only 5 (71.4) 0.990
Age (SD)a 47 (11.1) 56 (11.0) < 0.001
Venous events only 53 (11.2) 0.007
Arterial events only 58 (11.0) < 0.001
Both events only 58 (7.7) 0.008
Caucasian (%) 92 (46.5) 61 (71.8) < 0.001
Venous events only 25 (67.6) 0.018
Arterial events only 29 (70.7) 0.005
Both events only 5 (71.4) 0.005
CD4 nadir (IQR) 180 (67.5–300) 170 (65–275) 0.852
Venous events only 190 (70–275) 0.931
Arterial events only 170 (60–315) 0.874
Both events only 140 (40–260) 0.575
HIV RNA undetectable (%)a 168 (84.8) 78 (91.8) 0.114
Venous events only 35 (94.6) 0.113
Arterial events only 36 (87.8) 0.626
Both events only 7 (100) 0.265
cART usea 183 (92.4) 80 (94.1) 0.610
Venous events only 35 (94.6) 0.640
Arterial events only 38 (92.7) 0.954
Both events only 7 (100) 0.449
PI usea 58 (29.3) 31 (36.5) 0.233
Venous events only 13 (35.1) 0.477
Arterial events only 16 (39.0) 0.220
Both events only 2 (28.6) 0.967
aAt time of inclusion or at death; SD, Standard Deviation; IQR, Inter Quartile Range; cART,
Combination Antiretroviral Therapy; PI, Protease Inhibitor.
patients for the occurrence of a thrombotic event and by which
mechanism.
To answer the first question, we performed a retrospective
analysis. The incidence of arterial and thrombotic events com-
bined was 4.28 per 1000 PYO. We found an incidence of 2.21
per 1000 PYO of venous thrombotic events, which is more than
two-fold higher compared to healthy controls from large cohort
studies (Naess et al., 2007). This result corroborates with litera-
ture where the risk on venous thrombotic disease is reported to
be 2–10-fold increased (Klein et al., 2005; Crum-Cianflone et al.,
2008). The variation in observed incidences between studies is
probably related to the nature of these studies, mostly retrospec-
tive, the difference in diagnostic criteria and cohort characteris-
tics such as immune status of patients. An increasing amount of
evidence in the literature supports the notion that HIV status is
associated with increased risk on myocardial infarction, stroke
and venous thrombo-embolism (Micieli et al., 2007). With the
aging of HIV cohorts and related increased exposure to cART, it
remains important to re-evaluate this incidence rate. The inci-
dence rate for arterial events in our study was lower than previ-
ously found. Compared to the Data Collection on Adverse Events
of Anti-HIV Drugs (DAD) Study Group, the incidence in our
study is two-fold lower (d’Arminio et al., 2004). The prevalence
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FIGURE 2 | Plasma levels of LPS (N = 101), LBP (N = 130), sCD14
(N = 130), and vWF antigen (N = 93) in chronic HIV infected
individuals with or without a history of arterial or venous thrombotic
disease. Horizontal bar represents median for LPS, LBP, and sCD14; and
mean in vWF. Cases had a significantly higher vWF antigen level as
compared to controls. Gray, controls without a thrombotic event; red, arterial
events; blue, venous events; green, both arterial and venous events. LPS,
Lipopolysaccharide; LBP, LPS binding protein; sCD14, soluble CD14; vWF,
von Willebrand Factor antigen level. ∗p = 0.024 for venous events vs.
controls.
of risk factors such as smoking, diabetes and hypertension, were
comparable in both studies. One difference is a high use of PI’s in
the DAD study cohort. PI’s are known to cause metabolic abnor-
malities and could add in disease severity, although a direct causal
relationship with arterial disease remains controversial (Sklar and
Masur, 2003).
In HIV infection, several well-defined coagulation
abnormalities exist, such as Activated Protein C resistance,
Protein S deficiency, increased D-dimer, Tissue Factor expres-
sion on monocytes and increased levels of vWF. In this study,
we choose to examine vWF as a prognostic marker to investigate
the predisposition to a thrombotic event. This protein is crucial
in both primary and secondary hemostasis. It is produced
almost exclusively in the endothelium and is stored as large
multimers in vesicles called Weibel Palade bodies. The vWF
antigen level in HIV patients was two-fold higher compared
to the reference material (i.e., healthy donors), which implies
an increased coagulation potential in all HIV infected patients.
Several mechanisms could potentially result in a high level
of vWF antigen. A delayed clearance of vWF, as is seen in
conditions such as thrombotic thrombocytopenic purpura
(TTP) and hemolytic uremic syndrome (HUS), is unlikely the
cause of high vWF antigen in HIV. The activity of ADAMTS13,
the metalloproteinase responsible for clearing vWF, can be
lower in HIV, but does not reach the levels needed for overt
pathology (Jong et al., unpublished data; Badenhorst et al., 2009).
In addition, antibodies against ADAMTS13 are incidental in
HIV related TTP (Gunther et al., 2007). It seems more logical
to attribute the high vWF to increased transcriptional activity
in endothelial cells due to chronic immune activation (Baker,
2013). The production, storage and exocytosis of vWF are
regulated through intrinsic and extrinsic factors such as, but not
limited to nitric oxide, hypoxia, histamine, thrombin and other
secretagogues. LPS, for instance, could be a potent stimulator
of endothelial cells. Therefore, we explored the possibility
of immune activation as a driving factor behind arterial and
venous thrombosis. It is likely that monocytes rather than
T-cells are responsible for the initial immunologic response to
LPS translocation, considering these cells express CD14 and
TLR4, the receptors for LPS. Although markers of coagulation
and immune activation are partially restored upon initiation
of cART, a complete normalization fails to appear (Jong et al.,
2009; Funderburg, 2014). In the SMART study, a study aimed to
investigate the benefit of a CD4 guided approach on treatment
(El-Sadr et al., 2006), markers of inflammation and coagulation
such as IL-6, D-dimer and sCD14 were shown to be excellent
predictors of atherosclerosis and mortality (Kuller et al., 2008;
Sandler et al., 2011; Kelesidis et al., 2012). If immune activation
is chronic and predisposes patients for morbidity, we expected
to find higher baseline levels of these markers in patients with
a thrombotic event in the past. Although levels of immune
activation tended to be at the high end in all patients, we could
not detect a significant difference between cases and controls.
Correlation analysis revealed only a significant correlation
between sCD14 and LPS (Figure 5A). This could represent the
increased inflammatory response of monocytes on microbial
products. It is reasonable to assume that immunologic and
hemostatic factors can mutually influence each other. However,
all the other associations we describe in this manuscript were
non-significant.
Taken together, these data support the hypothesis of an
increased activity in coagulation, although the exact mechanism
remains to be elucidated. The presence of endothelial cell activa-
tion, increased fibrin formation and decreased anticoagulation,
as observed in HIV infected patients, is compatible with a pro-
thrombotic state (Jong et al., 2010; Arildsen et al., 2013) and
mirror markers of immune activation (Eastburn et al., 2011).
Additive pro-coagulant mechanisms such as increased tissue
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FIGURE 3 | vWF antigen in individuals with HIV without thrombosis
compared to HIV infected individuals with a recurrent venous or
arterial trombotic event. Patients with a recurrent venous thrombotic event
had a statistically significant higher vWF (p = 0.043). vWF, von Willebrand
Factor antigen level.
factor activity on monocytes as proposed by Funderburg et al.
(2010) could be involved alongside endothelial cell activation. In
the end, the model of chronic immune activation as proposed
by Brenchley et al. (2006), has given rise to new insights in the
pro-thrombotic state in HIV. In the meanwhile, we should con-
sider HIV as an independent risk factor for thrombosis. Possible
strategies to further investigate immune activation as a causative
mechanism could include the use of anti-inflammatory agents
or early initiation of therapy. Further research on the specific
interaction between endothelial cells and monocytes during HIV
infection would be especially interesting. Caution has to be made
in conferring primary prevention of thrombosis in HIV patients,
since anti-coagulation has potentially serious side effects. It may
be worth considering extending secondary prophylaxis in HIV
patients with a history of venous thrombosis, since the recur-
rence rate is relatively high. Although we found a significant
difference in vWF between venous recurrences and controls,
FIGURE 4 | Time from event to blood sample collection plotted against
vWF antigen level in HIV infected individuals with an arterial or venous
event. The level of vWF antigen is considerably higher than the reference
value. vWF, von Willebrand Factor antigen. Red, arterial events; blue, venous
events; green, both arterial and venous events. Light blue area, reference value
for vWF antigen level.
the wide distribution of values prevents an accurate discrimina-
tion between these two, limiting vWF as a predictor for venous
thrombosis.
The strength of our study is the detailed baseline demographic
and clinical data recorded from a well-characterized population
in the SHM cohort. Our study does have several limitations.
The study is retrospective, relying largely on the quality of exist-
ing data. We are aware of the fact that our data reflect only
documented thrombotic events, so the incidence calculated in
our study probably underestimates the real number. The ideal
study would be a prospective study with comparable person years
of inclusion and blood samples before and after an event. We
realize this is a laborious task considering practical issues. In
addition, HIV-positive patients weremostly on cART, so the indi-
vidual contribution of HIV infection and cART to immune acti-
vation biomarkers could not be distinguished. Our experiments
could not establish a relationship between LPS, LBP, sCD14 and
event status. A possible explanation could be the large interval
between occurrence of the event and measurement of the param-
eters (mean = 6.2 years later). We would expect a higher level
of immune activation markers around the time of the event.
Although microbial translocation has gained much attention as a
potential driver for immune activation, it should be stated other
mechanisms have not been addressed in this study. We cannot
exclude other potential mechanisms such as residual viral repli-
cation, CMV seropositivity and pyroptosis (Doitsh et al., 2014) as
a driver for coagulation abnormalities.
In conclusion, our study confirms previous findings that
HIV-infection results in a pro-thrombotic state, reflected by a
high incidence in venous thrombotic events and a high per-
centage that experiences a recurrence. Although we did not see
a clear association between markers of immune activation to
event status, we did encounter a significant difference in vWF
levels between patients with a past venous thrombo-embolism
and those without. These data support the rationale to extend
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FIGURE 5 | Correlation analysis of sCD14 vs LPS (log-transformed)
(A), sCD14 vs LBP (B), LBP vs LPS (log-transformed) (C), vWF vs
sCD14 (D), vWF vs LBP (E) and vWF vs LPS (log-transformed) (F). A
Spearman’s Rank-order test was used for analysis. Only sCD14 and LPS
(log-transformed) had a statistically significant correlation (A). There was a
weak trend toward positive correlation between vWF and sCD14 (D). LPS,
Lipopolysaccharide; LBP, LPS binding protein; sCD14, soluble CD14; vWF,
von Willebrand Factor antigen level.
anticoagulant therapy once venous thrombosis has occurred.
However, further investigation on, e.g., fVIII and other pro-
coagulants are needed. The wide distribution of vWF in our
patient groups does not support the use of thismarker as a clinical
predictor for recurrent thrombosis in HIV patients.
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